Perpetual Ltd Has $515,000 Stock Holdings in Astrazeneca Plc $AZN
Perpetual Ltd significantly reduced its stake in AstraZeneca Plc (NYSE:AZN) by 60.3% in the fourth quarter, selling 8,513 shares and holding 5,606 shares valued at $515,000. Despite this reduction, analyst coverage remains largely positive, with a "Moderate Buy" consensus and a target price of $95.75. AstraZeneca also recently announced a dividend of $1.595 per share, paid on March 23rd, and maintains a market capitalization of $315.33 billion.
Orthopaedics Market Set to Boom Rapidly by 2033 | Smith & Nephew • DePuy Synthes • NuVasive
Coherent Market Insights has released a comprehensive report titled "Orthopaedics Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033," predicting rapid growth in the orthopaedics sector. The report analyzes market competition, geographic distribution, and growth potential, covering industry performance, success factors, and economic analysis. It serves as a vital tool for entrepreneurs, investors, and business strategists, highlighting major market players like Johnson & Johnson, Stryker Corporation, and Zimmer Biomet.
Value Stock Risks: Analyst Concerns on 3 Companies in 2026 - News and Statistics
StockStory's analysis highlights three value stocks—Zimmer Biomet, Renasant, and Eastern Bankshares—as potentially risky investments for 2026 due to concerns over future performance despite current valuations. Zimmer Biomet faces issues with below-peer revenue growth and low returns on capital. Renasant shows slow revenue growth and declining earnings per share, while Eastern Bankshares struggles with credit quality and low return on equity.
Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Edwards Lifesciences Corporation (NYSE:EW) has received a "Moderate Buy" consensus recommendation from 28 research firms, with 16 analysts issuing a buy and three a strong buy rating. The average 12-month price target for the stock is $95.9565. Recent insider selling has been noted, including transactions by VP Daniel J. Lippis and CFO Scott B. Ullem, while institutional investors have adjusted their holdings.
Zimmer Biomet Holdings, Inc. (ZBH) stock price, news, quote and history
This page provides a comprehensive overview of Zimmer Biomet Holdings, Inc. (ZBH) stock, including real-time quotes, historical data, company profile, and financial analysis. It details the company's performance metrics, recent news, analyst ratings, and compares it with similar medical device companies. The content also highlights key financial figures and upcoming earnings dates for ZBH investors.
Zimmer Biomet (NYSE: ZBH) exec vests 6,626 RSUs; 1,677 shares withheld
Zimmer Biomet Holdings executive Noor Jehanzeb reported the vesting and exercise of 6,626 restricted stock units (RSUs) on April 1, 2026. To cover tax obligations, 1,677 shares were withheld at $90.67 per share, a non-market disposition. After these transactions, Jehanzeb directly holds 5,151 shares and 13,249 RSUs, with future vesting scheduled through April 1, 2028.
Zimmer Biomet (NYSE: ZBH) director receives 154 Phantom Stock Units in deferred award
Zimmer Biomet Holdings director Devdatt Kurdikar was granted 154.356 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors, bringing his total holdings to 1,928.847 units. These units, which include 4.508 units accrued through dividend reinvestment, are tied 1-for-1 to common shares and will be settled in shares of Zimmer Biomet common stock within sixty days after his service as a director ends. The transaction was reported in a Form 4 filing, with the units initially valued at $0.0000 per unit.
Q3 2025 Zimmer Biomet Holdings Inc Earnings Call Transcript
This article provides the transcript and key points from Zimmer Biomet Holdings Inc's Q3 2025 earnings call. The company reported a 5% sales growth and a 9.2% increase in adjusted EPS, driven by strong US performance and robotic placements. However, it faced challenges in Eastern Europe, Latin America, and non-core segments, leading to a lowered full-year revenue growth outlook and issues with commercial execution.
Zimmer Biomet (NYSE: ZBH) director receives new phantom stock unit grant
Zimmer Biomet's director, Maria Teresa Hilado, received a grant of 378.873 phantom stock units as part of her non-employee director compensation, increasing her total holdings to 11,684.719 units. These units, which include 30.381 units from dividend reinvestment, will be settled in cash through ten annual installments after her board service ends. Phantom stock units are cash-settled awards tied to the company's common stock value, providing economic exposure without actual share issuance.
Zimmer Biomet (NYSE: ZBH) director adds phantom stock units award
Zimmer Biomet Holdings, Inc. director Arthur J. Higgins received a grant of 308.711 phantom stock units on March 31, 2026, as part of the company's Deferred Compensation Plan for Non-Employee Directors. These units, which are convertible on a 1-for-1 basis with common stock but settled in cash, will be paid out in ten annual installments after his service ends. Following this award and dividend reinvestment, Higgins now holds a total of 36,375.195 phantom stock units.
Zimmer Biomet (NYSE: ZBH) director adds phantom stock units in deferred award
Zimmer Biomet director Robert Hagemann was granted 308.711 phantom stock units, increasing his total deferred balance to 31,982.841 units. These units, which track the company's common stock value, were accrued under the Deferred Compensation Plan for Non-Employee Directors and will be settled in cash in five annual installments after his board service concludes. The filing highlights the impact of non-employee director compensation through phantom stock units, which are common in deferred compensation plans.
Matrix Asset Advisors Inc. NY Sells 90,174 Shares of Zimmer Biomet Holdings, Inc. $ZBH
Matrix Asset Advisors Inc. NY significantly reduced its stake in Zimmer Biomet Holdings, Inc. by 75% in Q4, selling 90,174 shares and now holding 30,032 shares valued at approximately $2.7 million. Zimmer Biomet recently reported Q4 earnings that slightly beat estimates, with FY2026 EPS guidance of $8.30-$8.45, but analyst sentiment remains mixed with several recent "sell" downgrades. The company also announced a quarterly dividend of $0.24 per share.
Pictet North America Advisors SA Has $8.54 Million Stock Holdings in Astrazeneca Plc $AZN
Pictet North America Advisors SA reduced its stake in AstraZeneca Plc by 7.4% in the fourth quarter, now holding 92,910 shares valued at $8.541 million. Other institutional investors also adjusted their holdings in AstraZeneca, which recently paid a dividend of $1.595 per share. Analysts have a "Moderate Buy" consensus rating for AstraZeneca with a target price of $95.75.
Johnson & Johnson Vision leader explains significance of latest IOL milestone
Johnson & Johnson Vision received FDA approval for its Tecnis PureSee intraocular lens (IOL), designed to provide patients with an extended depth of focus and clear vision with minimal visual disturbances. Peter Menziuso, Company Group Chair, Vision, Johnson & Johnson, emphasized that this IOL is the first and only EDOF IOL in the U.S. without a warning on loss of contrast sensitivity, offering a significant advancement in cataract care. He highlighted the importance of personalized options for patients and surgeons, expanding the Tecnis platform to address a wide range of visual needs.
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
Regentis Biomaterials has appointed Ori Gon as Chief Financial Officer and Chief Business Officer to lead the company's financial strategy, planning, reporting, and commercial and business development activities. Gon's appointment comes as Regentis looks to commercialize its GelrinC hydrogel implant for knee cartilage repair in Europe following CE Mark approval and continues its pivotal Phase III FDA trial in the U.S. GelrinC offers a highly effective, off-the-shelf solution for focal articular knee cartilage injuries, with over 50% enrollment completed in its U.S. FDA study.
World Arthroscopy Devices - Market Analysis, Forecast, Size, Trends and Insights
The global arthroscopy devices market is expected to grow at a 6.2% CAGR from 2026 to 2035, driven by an aging population, rising sports injuries, and technological advancements. The market is shifting from capital equipment to consumables, with knee and shoulder arthroscopy being the largest segments. North America currently holds the largest market share, while Asia-Pacific is projected for the fastest growth.
A2Z Cust2Mate Solutions (NASDAQ:AZ) Posts Earnings Results, Beats Expectations By $0.49 EPS
A2Z Cust2Mate Solutions (NASDAQ:AZ) reported quarterly earnings of $0.39 per share, surpassing analyst estimates by $0.49, despite revenue missing expectations at $3.65 million. The company announced a $20 million share repurchase program and analysts have a mixed view with a consensus price target of $15.00.
Emerging Sub-Segments Transforming the Medical Device Subscription Market Landscape
The medical device subscription market is projected to reach $24.89 billion by 2030, growing at a CAGR of 22.5%, driven by remote monitoring, AI, and telehealth integration. Key players like Thermo Fisher Scientific and Medtronic are shaping the industry, with innovations like next-generation health wearables fostering personalized wellness management. The market is segmented by device type, subscription model, application, and end-user, including diagnostic, therapeutic, and monitoring devices across various medical fields.
Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC reduced its stake in Zimmer Biomet Holdings, Inc. by 31.5% in the fourth quarter, selling 15,033 shares. Despite this, Zimmer Biomet reported strong Q results, topping revenue and EPS estimates, and declared a quarterly dividend. Other institutional investors, however, increased their holdings in the medical equipment provider.
Future Perspectives: Key Trends Shaping the Intramedullary Nails Market up to 2030
The intramedullary nails market is expected to reach $1.32 billion by 2030, growing at a CAGR of 7.1%, driven by technological advancements, an aging population, and increasing trauma surgeries. Key trends include the adoption of minimally invasive procedures, anatomically tailored nails, and the focus on early patient mobilization. Leading companies are developing multifunctional, motorized devices, with a significant merger between Orthofix Medical Inc. and SeaSpine Holdings Corporation enhancing market capabilities.
[ARS] ZIMMER BIOMET HOLDINGS, INC. SEC Filing
This article announces an SEC ARS filing by Zimmer Biomet Holdings, Inc. (ZBH) on April 1, 2026. The filing is categorized with low impact and neutral sentiment. It also provides an overview of ZBH's stock performance rankings, recent news, and other SEC filings.
Moody Lynn & Lieberson LLC Increases Holdings in Astrazeneca Plc $AZN
Moody Lynn & Lieberson LLC significantly increased its stake in AstraZeneca Plc by 89.1% in the fourth quarter, now holding 47,878 shares valued at approximately $4.401 million. This increase reflects broadly positive analyst sentiment, with a "Moderate Buy" consensus rating and an average price target of $95.75. AstraZeneca also recently paid a dividend of $1.595, yielding 156.0%.
Edwards Lifesciences Corporation $EW Shares Acquired by J. Safra Sarasin Holding AG
J. Safra Sarasin Holding AG significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 139.5% during the 4th quarter, now owning 32,466 shares valued at $2.77 million. Other institutional investors also raised their positions, with institutional ownership reaching 79.46%. Despite some analysts maintaining "hold" ratings, the stock holds a consensus "Moderate Buy" rating with a target price of $96.14.
OrthoPediatrics Corp Stock: Specialized Pediatric Orthopedics Leader Faces Sector Headwinds and Grow
OrthoPediatrics Corp (NASDAQ: KIDS) is highlighted as a leader in specialized pediatric orthopedic solutions, serving a niche market distinct from larger competitors. The company's business model involves direct sales of implants and devices for trauma, deformity, spine, and sports medicine in children, supported by ongoing R&D and strategic acquisitions. While benefiting from high barriers to entry and strong clinical evidence, investors should consider risks such as reimbursement changes, sales force dependence, and competitive pressures.
Trends in Growth, Segment Analysis, and Competitive Approaches
The hand-held surgical instruments market is projected to reach $12.96 billion by 2030, growing at an 11.5% CAGR, driven by advanced surgical techniques, infection prevention, and outpatient surgeries. Key players include Johnson & Johnson, B. Braun Melsungen AG, and Zimmer Biomet Holdings Inc., with significant innovation seen in precision tools and ergonomic designs. Recent acquisitions, such as STERIS PLC's purchase of Becton, Dickinson and Company's surgical assets, are shaping the competitive landscape.
In-Depth Examination of Segments, Industry Developments, and Key Players in the Foot and Ankle Devices Market
The foot and ankle devices market is projected to reach $10.77 billion by 2030, growing at a CAGR of 10.2%, driven by advancements in orthopedic care and evolving patient needs. Key trends include customized orthopedic implants, advanced bracing, minimally invasive procedures, and diabetic foot care devices. Technological innovations, such as navigation systems for surgical accuracy, are also significantly impacting the market.
Zimmer Biomet Holdings Inc. stock rises Tuesday, still underperforms market
Shares of Zimmer Biomet Holdings Inc. (ZBH) rose 2.31% on Tuesday, closing at $90.42. This gain occurred during a favorable trading session where the S&P 500 Index and Dow Jones Industrial Average also saw significant increases, though ZBH still underperformed the broader market. This marks the second consecutive day of gains for the stock.
Zimmer Biomet Holdings, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
Zimmer Biomet Holdings, Inc. has seen a technical trend adjustment with its stock price slightly decreasing and has underperformed the S&P 500 over the past year and three years. Technical indicators present a mixed outlook, with both bullish and bearish signals across different timeframes and metrics. The company faces challenges in regaining market momentum within the competitive pharmaceuticals and biotechnology sector.
Stryker promotes two finance executives in leadership shift
Stryker (NYSE: SYK) has announced key financial leadership changes, effective May 1, 2026. Nick Mead, with nearly 20 years at the company, has been appointed Vice President, Investor Relations, while Jason Beach will transition to Vice President, Group Chief Financial Officer, MedSurg and Neurotechnology. These internal promotions aim to ensure continuity in finance and investor communications for the medical technologies leader.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of "Hold" by Analysts
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received an average "Hold" recommendation from 22 research firms, with an average 12-month target price of $106.20. The company recently reported Q4 earnings per share of $2.42 and revenue of $2.24 billion, both exceeding analyst expectations, and declared a quarterly dividend of $0.24. Insider activity shows a senior VP selling shares, though institutional investors hold a significant portion of the stock.
Zimmer Biomet Analysts Recommend 'Hold' Rating
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has received a consensus 'Hold' rating from 22 research firms, with an average 12-month price target of $106.20. Analysts note limited near-term upside due to factors like pricing pressure and market share challenges, despite the company's diversified product portfolio. Investors are awaiting the next quarterly earnings report in early May 2026 for further insights.
Zimmer Biomet (ZBH) Valuation Check After New Orthopedic And Digital Health Awards
Zimmer Biomet (ZBH) has recently received three Healthcare Asia Medtech Awards for its orthopedic and digital health tools, yet its stock performance has been subdued, with significant declines over the past year. Despite this, analyst narratives suggest the company is undervalued, trading at a 48% intrinsic discount and a 16% gap to analyst targets, indicating a potential investment opportunity. The undervaluation is supported by Zimmer Biomet's focus on digital health, robotics, and data-driven surgical solutions, which are expected to drive margin expansion and recurring revenues, though execution risks like pricing pressure remain.
Argus reiterates Zimmer Biomet stock rating on restructuring plan
Argus has reiterated a Buy rating and a $125.00 price target for Zimmer Biomet (NYSE:ZBH), citing the company's U.S. sales force restructuring aimed at driving long-term orthopedic growth. While the restructuring might result in slower sales growth in 2026, it is expected to lead to higher and sustainable growth from 2027 onward. The stock's current valuation is considered attractive by Argus, despite recent downgrades by other analysts.
Zimmer Biomet (ZBH) Valuation Check After New Orthopedic And Digital Health Awards
Zimmer Biomet Holdings (ZBH) recently received three Healthcare Asia Medtech Awards 2026 for its orthopedic and digital health innovations, yet its share price has declined, suggesting investor caution. Despite this, the company is estimated to be undervalued by 48% with an intrinsic value of $103, as its focus on digital health, robotics, and data-driven surgical solutions is expected to drive margin expansion and recurring revenues. However, the article notes potential risks from pricing pressure and competition in robotics and orthopedics.
Wedge Capital Management L L P NC Has $4.51 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH
Wedge Capital Management L L P NC reduced its stake in Zimmer Biomet Holdings, Inc. (ZBH) by 21.6% in the fourth quarter, selling 13,812 shares to hold 50,102 shares valued at $4.51 million. Despite this, other institutions like SG Americas Securities LLC increased their positions, and institutional ownership of ZBH remains high at 88.89%. Zimmer Biomet reported strong Q4 earnings, surpassing analyst estimates for EPS and revenue, and declared a quarterly dividend, while analysts maintain a "Hold" consensus rating with a $106.20 price target.
Global Knee Surgical Impactor Market to Reach USD 1,685.9 Million by 2036, Led by USA, China & India | Stryker, Zimmer Biomet, Johnson & Johnson Drive Precision Innovation
The global knee surgical impactor market is projected to grow to USD 1,685.9 million by 2036, exhibiting a 10.0% CAGR, driven by an aging population, rising osteoarthritis cases, and the need for precision in Total Knee Arthroplasty (TKA). The market, currently valued at USD 650.0 million in 2026, is seeing strong demand for advanced pneumatic and electro-pneumatic systems to ensure consistent implant alignment and reduce surgeon fatigue. The USA, China, and India are leading this growth, with companies like Stryker, Zimmer Biomet, and Johnson & Johnson spearheading innovation.
SG Americas Securities LLC Purchases 42,352 Shares of Zimmer Biomet Holdings, Inc. $ZBH
SG Americas Securities LLC significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, purchasing 42,352 additional shares and bringing its total holdings to 103,462 shares valued at approximately $9.30 million. This move comes as Zimmer Biomet beat analyst estimates for Q4 2026 earnings and revenue and provided optimistic FY2026 guidance. Despite a consensus "Hold" rating from analysts, institutional investors collectively own a substantial portion of the company's stock, with some insiders also adjusting their positions.
Does WalkAI’s Medtech Accolades Recast Zimmer Biomet’s (ZBH) Edge in Orthopedic and Digital Health?
Zimmer Biomet recently received three Healthcare Asia Medtech Awards for its innovations, including the AI-powered WalkAI platform. This recognition reinforces the company’s focus on integrating digital health and AI with traditional orthopedic implants to improve patient care and support its investment narrative. While the awards highlight Zimmer Biomet's connected, data-centric ecosystem, investors should also consider the challenges associated with integrating acquisitions and managing pricing pressures.
Stryker Corp. Stock: A Leader in Medtech with Strong Fundamentals Amid Evolving Market Dynamics
Stryker Corp. (ISIN: US8636671013) is highlighted as a leading medical technology company, excelling in orthopedics, surgical equipment, and neurotechnology with a strong focus on innovation and R&D. The article details its robust business model, market leadership in key product areas like robotic-arm assisted surgery, and its appeal to North American investors due to its stability, growth potential, and defensive qualities. However, it also addresses risks such as regulatory scrutiny, supply chain vulnerabilities, and competitive pressures within the evolving medtech landscape.
DXCM (DexCom) Earnings Power Value (EPV) : $11.42 (As of Dec25)
This article from GuruFocus.com details the Earnings Power Value (EPV) of DexCom (DXCM), finding it to be $11.42 as of December 25th. The analysis labels DXCM as "Significantly Undervalued" with a GF Score of 91/100, despite having 3 warning signs. The article explains the EPV methodology, which values a stock based on current free cash flow rather than speculative future projections.
Why is Zimmer (ZBH) down 2% since last earnings report?
The article "Why is Zimmer (ZBH) down 2% since last earnings report?" is currently empty, so no summary can be provided. The content consists only of "MSN".
Should You Buy Zimmer Biomet Holdings, Inc. (NYSE:ZBH) For Its Upcoming Dividend?
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is set to pay a dividend, and investors need to buy shares before the ex-dividend date of March 31st to receive it. The company demonstrates strong dividend sustainability with a low payout ratio of 27% of earnings and 17% of free cash flow, coupled with robust earnings per share growth of 18% annually over the last five years. This indicates a promising outlook for the dividend, as the company efficiently reinvests in its growth while maintaining a steady payout.
Align Technology (ALGN) $4.0B 2025 revenue, board refreshment and 2026 proxy
Align Technology's 2026 Proxy Statement details its 2025 financial results, including $4.0 billion in net revenues, and outlines strategic priorities such as international expansion and AI-enabled treatment enhancements. The company is also proposing governance changes, including board refreshment and adjustments to executive compensation to better align with stockholder interests. Stockholders will vote on these proposals, as well as the election of ten directors and the ratification of the independent auditor, at the virtual annual meeting on May 20, 2026.
Medtronic gets FDA clearance to use one system in brain and ENT surgery
Medtronic received FDA clearance for its Stealth AXiS™ surgical system for cranial and ENT procedures on March 27, 2026. This system unifies planning, navigation, robotics, and AI-enabled tractography within the AiBLE™ ecosystem, having previously been cleared for spine procedures in February. The clearance allows surgeons to use the system with greater precision and real-time insights during complex cranial and ENT surgeries, building on Medtronic's strategy of providing connected technologies across multiple specialties on a single platform.
Vanguard disaggregates holdings; Zimmer Biomet (ZBH) shows 0 shares
The Vanguard Group has filed an Amendment No. 9 to a Schedule 13G/A for Zimmer Biomet Holdings Inc (ZBH), reporting 0 shares and 0% beneficial ownership. This change is due to an internal realignment effective January 12, 2026, allowing certain Vanguard subsidiaries to report their holdings separately, as per SEC Release No. 34-39538, rather than indicating a sale of shares. The filing is administrative, clarifying reporting procedures and beneficial ownership attribution following the realignment.
Astrazeneca (NYSE:AZN) Shares Gap Up - Here's What Happened
AstraZeneca (NYSE:AZN) shares gapped up pre-market, opening at $190.88 and trading around $190.35, up about 3.6%. The company has received largely positive analyst sentiment, with a "Moderate Buy" consensus rating and a consensus price target of $95.75, backed by recent reiterations from firms like Morgan Stanley and Barclays. AstraZeneca also disclosed a dividend of $1.595, reflecting a 156.0% yield, and reported strong company metrics including a market cap of $294.5 billion.
Should You Buy Zimmer Biomet Holdings, Inc. (NYSE:ZBH) For Its Upcoming Dividend?
Zimmer Biomet Holdings (NYSE:ZBH) is set to pay a dividend of US$0.24 per share, with an ex-dividend date of March 31st. The company demonstrates strong dividend sustainability, paying out only 27% of earnings and 17% of free cash flow, alongside significant earnings per share growth of 18% annually over the last five years. This combination of growth, conservative payout ratios, and reinvestment in the business suggests it could be an attractive option for dividend-focused investors.
Should You Buy Zimmer Biomet Holdings, Inc. (NYSE:ZBH) For Its Upcoming Dividend?
Zimmer Biomet Holdings (NYSE: ZBH) is set to trade ex-dividend shortly, with a payment of US$0.24 per share, resulting in a trailing yield of 1.1%. The company demonstrates strong dividend sustainability, paying out a modest 27% of earnings and 17% of free cash flow, alongside robust earnings per share growth of 18% over the past five years. This combination of growth, conservative payout ratios, and dividend increases suggests ZBH could be an attractive option for dividend-focused investors.
UAE Dental Devices Market Is Going to Boom Rapidly |3M Company,
This press release announces a market research report on the UAE Dental Devices Market, forecasting rapid growth between 2026 and 2033. The report offers detailed insights into market structure, segmentation, key players like 3M Company and Dentsply Sirona, and strategic recommendations for businesses. It covers product types, treatments, and end-user segments, aiming to help stakeholders capitalize on emerging opportunities in the evolving market landscape.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Zimmer Biomet Holdings Inc. (ZBH) saw its stock rally by 1.72% to $89.15 on Thursday, outperforming the broader market which experienced a significant downturn. The S&P 500 Index fell 1.74% and the Dow Jones Industrial Average fell 1.01% on the same trading day. This marks the second consecutive day of gains for Zimmer Biomet Holdings Inc.
